Droplet delivery for nicotine compositions

By formulating nicotine compositions with excipients to control droplet size and irritation, the device addresses the challenge of optimal droplet production in nicotine delivery, enhancing user experience and aligning with traditional smoking or vaping sensations.

US20260354440A1Pending Publication Date: 2026-11-12PNEUMA RESPIRATORY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
US19/669484
Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Priority Date
2025-10-15
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing nicotine delivery devices struggle to produce droplets of optimal size for inhalation, leading to user irritation and suboptimal sensory experience, as larger droplets cause irritation while smaller droplets may not be felt, and the concentration of nicotine affects droplet size and irritation independently.

Method used

The formulation of nicotine compositions includes specific excipients and adjustments to properties like viscosity, surface tension, and evaporation rate to control droplet size, using a push-mode droplet delivery device to produce droplets with an average mass median aerodynamic diameter (MMAD) between 0.5 to 3 micrometers, minimizing user irritation and enhancing sensory experience.

Benefits of technology

The controlled droplet size and composition optimize the sensory experience by reducing irritation and improving palatability, aligning with user expectations similar to traditional smoking or vaping, while allowing for gradual nicotine reduction through varying concentration cartridges.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US20260354440A1-D00000_ABST
    Figure US20260354440A1-D00000_ABST
Patent Text Reader

Abstract

Compositions, aerosolized compositions, cartridges, devices, systems, and methods are disclosed for delivering nicotine using a droplet delivery device. In embodiments, an aqueous composition comprises nicotine or a salt thereof, lactic acid or a salt thereof, and water, and aerosolization using a push-mode droplet delivery device produces droplets having an average MMAD less than 3 micrometers. In embodiments, the composition comprises nicotine or a salt thereof with ascorbic acid or a salt thereof and citric acid or a salt thereof. Devices can include an electronically actuated ejector in fluid communication with a container or replaceable cartridge containing the composition. Kits can include cartridges having different nicotine concentrations for smoking cessation or nicotine tapering.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of U.S. Provisional App. No. 63 / 800,862 filed May 6, 2025, and U.S. Provisional App. No. 63 / 899,515 filed Oct. 15, 2025, all of which are incorporated herein by reference in their entireties for all purposes.BACKGROUND

[0002] Embodiments of the instant disclosure generally relate to compositions and methods for administering nicotine and nicotine-containing compositions to the respiratory system. This application incorporates the disclosures of U.S. patent application Ser. No. 18 / 986,462 filed Dec. 18, 2024 and PCT / US2025 / 013898 filed Jan. 30, 2025, WO 2020 / 264501 filed Jun. 29, 2020 (describing “Ring Mode” Droplet Devices), and U.S. Pat. No. 11,793,945 (describing “Push Mode” Droplet Devices) herein by reference in their entireties for all purposes. This application also incorporates the disclosures of U.S. Pat. Nos. 9,962,507, 9,956,360, and 12,161,795, U.S. App. Pat. Pub. Nos. 2022 / 0296823, 2025 / 0228876, 2023 / 0286008, 2026 / 0027309, 2025 / 0194661, 2025 / 0275572, and 2025 / 0276134, U.S. Provisional App. Nos. 63 / 905,270, 64 / 001,704 and 64 / 053,935, and WO 2025 / 101933, WO 2023 / 215389, WO 2024 / 020047, WO 2025 / 166083, WO 2024 / 151663, WO 2025 / 006626, WO 2025 / 122635, WO 2025 / 166081, WO 2025 / 217537, WO 2025 / 217641, PCT / 2025 / 049918, PCT / US2026 / 16283, by reference in their entireties for all purposes.SUMMARY OF THE INVENTION

[0003] In some embodiments, the disclosure provides compositions, aerosolized compositions, cartridges, droplet delivery devices, systems, and methods for delivering nicotine-containing compositions to the respiratory system. In embodiments, an aqueous nicotine composition is configured for use with a non-heated droplet delivery device, including a push-mode droplet delivery device, to produce droplets suitable for inhalation.

[0004] In some embodiments, the composition comprises nicotine, or a salt thereof, lactic acid, or a salt thereof, and water. In embodiments, aerosolization of the composition using a push-mode droplet delivery device produces droplets having an average mass median aerodynamic diameter (MMAD) less than 3 micrometers. In embodiments, the droplets have an average MMAD from 0.5 micrometers to 3 micrometers, including subranges thereof.

[0005] In some embodiments, the composition comprises nicotine, or a salt thereof, ascorbic acid, or a salt thereof, and citric acid, or a salt thereof. In embodiments, the composition comprises nicotine ascorbate and nicotine citrate. In further embodiments, the composition consists essentially of water, nicotine or a salt thereof, and one or more of lactic acid, ascorbic acid, citric acid, salts thereof, and flavoring compounds.

[0006] In some embodiments, the nicotine concentration, acid selection, water content, pH, viscosity, surface tension, density, evaporation rate, contact angle, and / or excipient content are selected to control droplet size, mouth feel, throat feel, irritation, taste, and / or uptake of nicotine. In embodiments, the composition comprises nicotine at a concentration from 0.1 wt. % to 2.5 wt. %, from 0.3 wt. % to 5.0 wt. %, or another concentration disclosed herein, and comprises water in an amount of at least 50 wt. % or at least 80 wt. %.

[0007] In some embodiments, the composition has a pH from 4.4 to 5.8, including from 5.0 to 5.4. In embodiments, the composition has a viscosity from 0.9 mm2 / s to 2.5 mm2 / s measured at 23 degrees Celsius and / or a surface tension from 40 mN / m to 70 mN / m. In embodiments, the composition includes one or more additional excipients selected from propylene glycol, ethanol, menthol, WS-23, a flavorant, a fruit extract, a tobacco flavor, a sweetener, an organic acid, a surfactant, a polymer, a carbohydrate, a preservative, a tonicity agent, a cyclodextrin, and combinations thereof.

[0008] In some embodiments, a droplet delivery device includes an electronically actuated ejector in fluid communication with a container or replaceable cartridge containing a nicotine-containing solution. In embodiments, the ejector is configured for push-mode ejection, and a membrane is disposed between an electronic actuator and the electronically actuated ejector. In embodiments, the replaceable cartridge comprises cyclohexylenedimethylene terephthalate glycol-modified plastic.

[0009] In some embodiments, a method of optimizing production of droplets for inhalation includes providing a first solution to an electronically actuated ejector of a droplet delivery device and generating droplets, and thereafter providing a second solution having a lower nicotine concentration than the first solution after determining that the first solution does not generate sufficiently small droplets from the droplet delivery device.

[0010] In some embodiments, a smoking cessation system includes a kit comprising a plurality of cartridges containing nicotine-containing compositions at different nicotine concentrations. In embodiments, a first cartridge includes nicotine or a salt thereof at a first concentration, and a second cartridge includes nicotine or a salt thereof at a second concentration lower than the first concentration, thereby permitting a user to reduce nicotine intake by progressing through cartridges having decreasing nicotine concentrations.BRIEF DESCRIPTION OF THE FIGURES

[0011] FIG. 1 is a graph illustrating MMAD for apple-flavored nicotine compositions at various concentrations.

[0012] FIG. 2 is a graph illustrating MMAD for cool mint-flavored nicotine compositions at various concentrations.

[0013] FIG. 3 is a graph illustrating MMAD for tobacco-flavored nicotine compositions at various concentrations.

[0014] FIG. 4 is a graph illustrating MMAD for unflavored nicotine compositions at various concentrations.

[0015] FIG. 5 is a cross-sectional view of a push-mode type droplet delivery device generating droplets from compositions disclosed herein in various embodiments.DETAILED DESCRIPTION

[0016] In a droplet delivery device, there are numerous factors that influence a user's sensory experience. Formulation is a critical aspect of this, particularly with nicotine delivery devices.

[0017] Formulation can influence the size of the droplets delivered by a device, the taste of the aerosol, the irritation or lack of irritation experienced by the user, etc.Droplet Size

[0018] In a droplet delivery device, the size of the droplets is important for the user experience. In certain applications, such as with a nicotine delivery device, larger droplets may be caustic and cause irritation to the user. Smaller droplets may not be felt by the user and may not create the optimal sensory experience. While the present application discusses droplet size, the inventions and formulations herein could also be applied to manipulate the amount of ejected mass produced upon aerosolization of a solution.

[0019] In a droplet delivery device that delivers active pharmaceutical ingredients (APIs) in therapeutic applications, targeting specific droplet sizes is important for targeted deposition within the respiratory tract. Droplet size may also be important from a sensory perspective, ensuring the inhaled aerosol is palatable for the user.

[0020] In a nicotine droplet delivery device, finding the ideal droplet size is important for optimizing sensory experience. Users may expect a level of irritation similar to that of a cigarette or e-cigarette. Therefore, the correct droplet size is required.

[0021] In a water-based nicotine droplet delivery device, the percentage of nicotine affects the droplet size delivered to the user.

[0022] In some embodiments, droplets are smaller with a lower amount of nicotine in them. The amount of nicotine in the water-based solution can be used to determine the level of irritation that a user feels by influencing the droplet size produced from the solution. In some embodiments, a solution containing a higher percentage of nicotine is supplied to a droplet delivery device to create larger droplet sizes. In some embodiments, a solution containing a lower percentage of nicotine is supplied to a droplet delivery device to create smaller droplet sizes.

[0023] Additionally, nicotine is caustic and causes irritation itself. Therefore, a greater concentration of nicotine will also result in more irritation to the user, independent of droplet size delivered.

[0024] In embodiments, droplet size is controlled though the selection of excipients as described herein. Adjusting the droplet size can minimize the irritation felt by the user. Excipients disclosed herein include, but are not limited to, polymers, surfactants, tonicity agents, preservatives, solvents such as propylene glycol, vegetable glycerin, glycerol, ethanol, flavoring compounds like menthol, WS-23, WS-5, neotame, other flavoring compounds, and the like. Additionally, the type of acid used with nicotine can affect the droplet size. This includes, but is not limited to, lactic acid, benzoic acid, hydrochloric acid, ascorbic acid, citric acid, acetic acid, and the like.

[0025] In some embodiments, controlling droplet size through the selection of excipients is used with droplet delivery devices intended to deliver one or more APIs in therapeutic applications. Exemplary APIs include, but are not limited to, albuterol sulfate, levalbuterol, formoterol, salmeterol, indacaterol, ipratropium bromide, tobramycin, tiotropium, glycopyrronium, aclidinium, fluticasone, budesonide, mometasone, or a combination thereof.

[0026] In some embodiments, controlling droplet size through the selection of excipients is used with droplet delivery devices intended to deliver one or more biologic drugs in therapeutic applications. Exemplary biologic drugs include, but are not limited to, therapeutic peptides, proteins, antibodies, and other bioengineered molecules include: growth factors, insulin, vaccines (Prevnor—Pneumonia, Gardasil—HPV), antibodies (Avastin, Humira, Remicade, Herceptin), Fc Fusion Proteins (Enbrel, Orencia), hormones (Elonva—long acting FSH, Growth Hormone), enzymes (Pulmozyme—rHu-DNAase-), other proteins (Clotting factors, Interleukins, Albumin), gene therapy and RNAi, cell therapy (Provenge—Prostate cancer vaccine), antibody drug conjugates—Adcetris (Brentuximab vedotin for HL), cytokines, anti-infective agents, polynucleotides, oligonucleotides (e.g., gene vectors), or any combination thereof; or solid particles or suspensions such as Flonase (fluticasone propionate) or Advair (fluticasone propionate and salmeterol xinafoate).

[0027] In some embodiments, excipients used in formulations include those approved by the FDA for inhalation. Excipients include, but are not limited to, 1,2-distearoyl-sn-glycero-3-phosphocholine, ethanol, citric acid, trisodium citrate, ascorbic acid, benzalkonium chloride, calcium carbonate, calcium chloride, carrageenan, cetylpyridinium chloride, chlorobutanol, edetate disodium, ferric oxide yellow, gelatin, glycerin, glycine, hydrochloric acid, lactose, magnesium stearate, mannitol, menthol, methylparaben, nitric acid, nutmeg oil, oleic acid, petrolatum, phenylethyl alcohol, polysorbate 80, potassium chloride, propylene glycol, propylparaben, saccharin, saccharin sodium, silicon dioxide, sodium bicarbonate, sodium bisulfate, sodium bisulfite, sodium chloride, sodium hydroxide, sodium lauryl sulfate, sodium metabisulfite, sodium sulfate, sorbitan trioleate, soybean lecithin, sulfuric acid, thymol, titanium dioxide, trichloromonofluoromethane, trisodium citrate dihydrate, tromethamine, and zinc oxide.

[0028] In some embodiments, evaporation rates achieve the effect that a formulation has on droplet size. Nicotine evaporates at a much slower rate than water. The heat of vaporization of water at 25 °C is around 44 kJ / mole. The heat of vaporization of pure nicotine at 25 °C is around 87 kJ / mole. The droplets that exit the droplet delivery device are initially very small. The droplets can be anywhere from 0.01 μm to 50 μm when they exit the droplet delivery device. The droplets immediately start to evaporate. According to William C. Hinds in “Aerosol Technology,” in 20 °C and 50% relative humidity, the lifetime (the amount of time it takes for a droplet to fully evaporate) of a 10 μm droplet is 0.15 s. And the lifetime of a 4.0 μm droplet is 0.024 s.

[0029] In some embodiments, the surface tension of the liquid achieves the effect on droplet size.

[0030] In some embodiments, the viscosity of the liquid achieves the effect on droplet size. For example, an excipient may be added to decrease the viscosity of a solution, which may lead to a smaller droplet size upon aerosolization of the solution.

[0031] In some embodiments, the density of the liquid achieves the effect on droplet size.

[0032] In some embodiments, the coefficient of thermal expansion achieves the effect on droplet size.

[0033] In some embodiments, the intermolecular forces, or Van der Waals forces, achieve the effect on droplet size.

[0034] In some embodiment, the capillary action achieves the effect on droplet size. The capillary action is dependent upon the surface tension of the liquid, the density of the liquid, the contact angle of the surface touching the liquid, the dimensions of the embodiment, gravity and / or other forces. A test can be done by seeing how high a liquid can rise in a glass tube to measure the capillary rise. The following equation is used to determine the capillary rise where “h” is the capillary rise, “T” is the surface tension, “θ” is the water contact angle of the surface of the glass, “r” is the radius of the glass tube, “ρ” is the density of the liquid, and “g” is the force of gravity.h=2⁢T⁢cos⁢θ r⁢ρ⁢g

[0035] In embodiments, a combination of evaporation rate, surface tension, and / or viscosity achieves the effect on droplet size.

[0036] In embodiments, a combination of one or more of evaporation rate, surface tension, viscosity, density, coefficient of thermal expansion, intermolecular forces, and / or capillary action achieves the effect on droplet size.

[0037] In some embodiments, one or more excipient(s) are added to a nicotine-containing solution to affect the droplet size created when the solution is supplied to a droplet delivery device. For example, the excipients could include, but are not limited to, polymers, tonicity agents, preservatives, solvents such as propylene glycol, ethanol, vegetable glycerin, glycerol, surfactants, etc. The excipient(s) can be added in higher or lower concentrations to increase or decrease the droplet size. In some embodiments, the excipient(s) change the viscosity of the solution, thereby affecting the droplet size created. In embodiments, the excipient(s) change the surface tension of the solution, thereby affecting the droplet size created. In some embodiments, the excipient(s) changes the surface tension and viscosity of the solution, thereby affecting the droplet size created. In embodiments, the excipient(s) may affect the droplet size independently of the viscosity or surface tension of the solution. In some embodiments, the excipient(s) changes a physical or chemical property of the solution other than surface tension and viscosity, thereby affecting the droplet size created.

[0038] In some embodiments, one or more excipient(s) are added to a solution containing one or more APIs to affect the droplet size created when the solution is supplied to a droplet delivery device. For example, the excipients could include, but are not limited to, polymers, tonicity agents, preservatives, solvents such as propylene glycol, ethanol, vegetable glycerin, glycerol, surfactants, etc. The excipient(s) can be added in higher or lower concentrations to increase or decrease the droplet size. In some embodiments, the excipient(s) change the viscosity of the solution, thereby affecting the droplet size created. In embodiments, the excipient(s) change the surface tension of the solution, thereby affecting the droplet size created. In some embodiments, the excipient(s) changes the surface tension and viscosity of the solution, thereby affecting the droplet size created. In embodiments, the excipient(s) may affect the droplet size independently of the viscosity or surface tension of the solution. In some embodiments, the excipient(s) changes a physical or chemical property of the solution other than surface tension and viscosity, thereby affecting the droplet size created.

[0039] In some embodiments, the change in one or more of the properties results in the evaporation rate affecting the final droplet size.

[0040] In some embodiments, the change in one or more of the properties results in the way the liquid exits the aperture of the aperture plate affecting the final droplet size.

[0041] In some embodiments, the change in one or more of the properties results in droplets splitting up as they exit the aperture of the aperture plate affecting the final droplet size.

[0042] In some embodiments, the change in one or more of the properties results in a change in pressure behind the aperture plate affecting the final droplet size.

[0043] In some embodiments, the way the solution interacts with the aperture plate affects the droplet size. For example, the contact angle between a solution and the aperture plate could affect the droplet size produced upon aerosolization of the solution. Altering a solution via addition or removal of excipients or by changing the concentration of components could be used to manipulate the droplet sized produce. Alternatively, the solution could be held constant, and the aperture plate material could be changed. The aperture plate material could be chosen based on the desired contact angle with a given solution.

[0044] Tables 2-5 provide data collected from various solutions used with a push mode droplet delivery device. The data illustrates the change in droplet size when using a range of nicotine concentrations. The formulations used for the testing are listed in Table 1.

[0045] Particle testing was performed using the Dekati ELPI+ which is an electrical low pressure impactor. The impactor is operated via the ELPI+VI software running on an external computer. The ELPI+ is connected to a Topaz model DIL 557 diluter with a ratio of 1:100. An external air tube and filter is attached to a flowrate device which is then connected by a T-connector. The other connection point is attached to a flexible tube that allows for the device to be connected. The combined airflow then goes into the diluter before entering the ELPI+. Since the ELPI+ is + / −0.2 LPM our EPLI+ flowrate was measured at 9.8 LPM. Due to this predetermined flowrate, the flowrate for the external air is set at 7.8 LPM, which means that the flowrate of the attached device would be equal to 2 LPM.TABLE 1The table below outlines the formulations used to collect the data shownin Tables 2-5. The apple and tobacco flavorings are manufactured by FLAVORIQ(Item Numbers: FQ.PNR0004 E-F Apple Sweet and FQ.PNR0009 E-F USA Mix).As used herein, % (w / w) and wt. % are used interchangeably.NameFormulation CompositionNo FlavorNicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2 inwaterTobaccoNicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2,propylene glycol 5% (w / w), tobacco flavoring <0.05% (w / w), neotame0.15% (w / w) in waterAppleNicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2,propylene glycol 10% (w / w), apple flavoring 0.3% (w / w), neotame 0.15%(w / w) in waterCool MintNicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2,propylene glycol 9.7% (w / w) L-menthol 0.04% (w / w), DL-menthol 0.03%(w / w), WS-23 0.3% (w / w), cornmint oil 0.1% (w / w), ethanol 2.4% (w / w),neotame 0.15% (w / w)Cool Mimic - ANicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2,propylene glycol 10%, ethanol 3%Cool Mimic - BNicotine lactate (0.6%, 1.2%, 1.8%, 3.0%, or 5.0%) (w / w) at pH of 5.2,propylene glycol 10%, ethanol 10%TABLE 2As a non-limiting example, the table below contains dropletsize data collected from a droplet delivery device. The datacollected is the mass median aerodynamic diameter (MMAD).Five nicotine percentages were tested with three differentdevices. All of the solutions included an apple flavoring.FIG. 1 illustrates a graph of the results of Table 2.Sample NumberNicotine Concentration (%)MMAD (μm)Apple 10.60.808Apple 11.20.899Apple 11.81.069Apple 13.01.209Apple 15.01.359Apple 20.60.749Apple 21.20.836Apple 21.80.959Apple 23.01.074Apple 25.01.238Apple 30.60.743Apple 31.20.801Apple 31.80.932Apple 33.00.992Apple 35.01.203TABLE 3As a non-limiting example, the table below contains droplet sizedata collected from a droplet delivery device. The data collectedis the MMAD. Five nicotine percentages were tested with three differentdevices. All of the solutions included a cool mint flavoring. FIG.2 illustrates a graph of the results of Table 3.Sample NumberNicotine Concentration (%)MMAD (μm)Cool Mint 10.60.914Cool Mint 11.21.026Cool Mint 11.81.011Cool Mint 13.01.194Cool Mint 15.01.350Cool Mint 20.60.738Cool Mint 21.20.872Cool Mint 21.80.997Cool Mint 23.01.191Cool Mint 25.01.260Cool Mint 30.60.741Cool Mint 31.20.821Cool Mint 31.80.935Cool Mint 33.01.098Cool Mint 35.01.172TABLE 4As a non-limiting example, the table below contains droplet sizedata collected from a droplet delivery device. The data collectedis the MMAD. Five nicotine percentages were tested with threedifferent devices. All of the solutions included a tobacco flavoring.FIG. 3 illustrates a graph of the results of Table 4.Sample NumberNicotine Concentration (%)MMAD (μm)Tobacco 10.60.842Tobacco 11.20.912Tobacco 11.80.997Tobacco 13.01.160Tobacco 15.01.329Tobacco 20.60.738Tobacco 21.20.872Tobacco 21.80.997Tobacco 23.01.191Tobacco 25.01.260Tobacco 30.60.741Tobacco 31.20.821Tobacco 31.80.935Tobacco 33.01.098Tobacco 35.01.172TABLE 5As a non-limiting example, the table below contains droplet sizedata collected from a droplet delivery device. The data collectedis the MMAD. Five nicotine percentages were tested with threedifferent devices. All of the solutions were unflavored. FIG.4 illustrates a graph of the results of Table 5.Sample numberNicotine Concentration (%)MMAD (μm)No Flavor 10.60.757No Flavor 11.20.997No Flavor 11.81.039No Flavor 13.01.162No Flavor 15.01.305No Flavor 20.60.724No Flavor 21.20.879No Flavor 21.80.982No Flavor 23.01.075No Flavor 25.01.236No Flavor 30.60.711No Flavor 31.20.831No Flavor 31.80.895No Flavor 33.01.009No Flavor 35.01.165NameMMAD0.6% NicotineNo Flavor-10.757AvgNo Flavor-20.7240.731No Flavor-30.7110.024Tobacco-10.842AvgTobacco-20.7380.774Tobacco-30.7410.059Apple-10.808AvgApple-20.7490.767Apple-30.7430.036Cool mint-10.914AvgCool mint-20.7380.798Cool mint-30.7410.1011.2% NicotineNo Flavor-10.997AvgNo Flavor-20.8790.902No Flavor-30.8310.085Tobacco-10.912AvgTobacco-20.8720.868Tobacco-30.8210.046Apple-10.899AvgApple-20.8360.845Apple-30.8010.050Cool mint-11.026AvgCool mint-20.8720.906Cool mint-30.8210.1071.8% NicotineNo Flavor-11.039AvgNo Flavor-20.9820.972No Flavor-30.8950.073Tobacco-10.997AvgTobacco-20.9970.976Tobacco-30.9350.036Apple-11.069AvgApple-20.9590.987Apple-30.9320.073Cool mint-11.011AvgCool mint-20.9970.981Cool mint-30.9350.0403.0% NicotineNo Flavor-11.162AvgNo Flavor-21.0751.082No Flavor-31.0090.077Tobacco-11.160AvgTobacco-21.1911.150Tobacco-31.0980.047Apple-11.209AvgApple-21.0741.092Apple-30.9920.110Cool mint-11.194AvgCool mint-21.1911.161Cool mint-31.0980.0555.0% NicotineNo Flavor-11.305AvgNo Flavor-21.2361.235No Flavor-31.1650.070Tobacco-11.329AvgTobacco-21.2601.254Tobacco-31.1720.079Apple-11.359AvgApple-21.2381.267Apple-31.2030.082Cool mint-11.350AvgCool mint-21.2601.261Cool mint-31.1720.089Physical attributes of the above compositions and MMAD values are reported in the following tables.DensityViscositySTContact(g / mL)(mm2 / s)(mN / m)angle (°)No Flavor 0.6%0.99890.90670.95100.96No Flavor 1.2%1.00090.93369.78N / ANo Flavor 1.8%1.00280.95968.8692.88No Flavor 3%1.00671.01567.66N / ANo Flavor 5%1.01321.12065.5992.89Tobacco 0.6%1.00261.06665.15N / ATobacco 1.2%1.00451.09864.42N / ATobacco 1.8%1.00661.13563.86N / ATobacco 3%1.01041.19563.17N / ATobacco 5%1.01711.32758.8N / AApple 0.6%1.00351.14249.7987.79Apple 1.2%1.00561.17652.09N / AApple 1.8%1.00751.20951.9884.88Apple 3%1.01151.28751.60N / AApple 5%1.01821.42550.9190.21Cool Mimic A 0.6%1.00151.40653.65N / ACool Mimic A 1.2%1.00361.45754.76N / ACool Mimic A 1.8%1.00571.49854.55N / ACool Mimic A 3%1.00961.60553.71N / ACool Mimic A 5%1.01661.77953.06N / ACool Mimic B 0.6%0.99141.82245.7980.67Cool Mimic B 1.2%0.99321.87443.82N / ACool Mimic B 1.8%0.99481.94043.2181.85Cool Mimic B 3%0.99892.05344.35N / ACool Mimic B 5%1.00542.27544.2969.793% EtOH No Flavor 0.6%0.99391.01861.52N / A3% EtOH No Flavor 1.2%0.99561.05160.76N / A3% EtOH No Flavor 1.8%0.99751.08160.30N / A3% EtOH No Flavor 3%1.00161.14160.29N / A3% EtOH No Flavor 5%1.00801.26058.23N / A10% EtOH No Flavor 0.6%0.98251.321N / AN / A10% EtOH No Flavor 1.2%0.98441.358N / AN / A10% EtOH No Flavor 1.8%0.98631.427N / AN / A10% EtOH No Flavor 3%0.99031.502N / AN / A10% EtOH No Flavor 5%0.99691.658N / AN / A30% EtOH No Flavor 0.6%0.95292.295N / AN / A30% EtOH No Flavor 1.2%0.95422.352N / AN / A30% EtOH No Flavor 1.8%0.95592.402N / AN / A30% EtOH No Flavor 3%0.95932.507N / AN / A30% EtOH No Flavor 5%0.96392.71N / AN / ADeviceDeviceDeviceDeviceJ3-02J3-03J3-04J3-08AverageStdMMADMMADMMADMMADMMADdev(μm)(μm)(μm)(μm)(μm)(μm)No Flavor 0.6%1.1600.6450.6461.5080.9900.422131No Flavor 1.2%0.7920.6780.6730.8100.7380.072858No Flavor 1.8%1.0640.8000.8931.0920.9620.139414No Flavor 3%0.9680.8841.2801.3111.1110.21644No Flavor 5%1.0531.0511.1521.1031.0900.047968Tobacco 0.6%0.7260.6380.7870.6000.6880.084634Tobacco 1.2%0.8730.8720.6300.7610.7840.11534Tobacco 1.8%0.8800.7430.7460.7620.7830.065368Tobacco 3%0.6700.9480.8330.8830.8340.118734Tobacco 5%1.0220.9400.9551.0991.0040.072677Apple 0.6%0.7971.0271.0310.6800.8840.174397Apple 1.2%0.8700.9360.7710.7460.8310.088262Apple 1.8%0.7290.7930.9870.8170.8320.11012Apple 3%0.8601.0870.8600.9350.9360.107009Apple 5%1.0001.0571.0211.1081.0470.047276Cool Mimic A 0.6%0.5190.7191.0330.6680.7350.216183Cool Mimic A 1.2%0.6240.7690.6110.8370.7100.110765Cool Mimic A 1.8%0.7270.7471.0980.7990.8430.172851Cool Mimic A 3%0.8570.8320.7771.0090.8690.099292Cool Mimic A 5%1.0011.0720.9201.1371.0330.093326Cool Mimic B 0.6%0.4400.6720.6660.6840.6160.117239Cool Mimic B 1.2%0.5810.8700.6260.6320.6770.1305Cool Mimic B 1.8%0.7040.7520.7420.9240.7810.097876Cool Mimic B 3%0.8300.8560.9711.0220.9200.091653Cool Mimic B 5%0.9910.9511.0141.0771.0080.0527093% EtOH No Flavor 0.6%0.8930.7700.7301.2700.9160.2461413% EtOH No Flavor 1.2%0.6120.9280.7000.7280.7420.1334873% EtOH No Flavor 1.8%0.7460.7590.7000.7680.7430.0302153% EtOH No Flavor 3%0.8420.9160.7890.8870.8590.0554413% EtOH No Flavor 5%1.0001.0500.9141.0601.0060.06671310% EtOH No Flavor0.880.8151.0250.8610.8950.0907020.6%10% EtOH No Flavor0.6090.6411.510.7230.8710.4288621.2%10% EtOH No Flavor0.7370.7690.7790.8490.7840.0471981.8%10% EtOH No Flavor 3%0.7650.7780.8760.8460.8160.05336910% EtOH No Flavor 5%0.8210.9541.0470.9720.9490.09405830% EtOH No Flavor0.3981.0470.4490.4940.5970.3025520.6%30% EtOH No Flavor0.6110.5940.6070.5060.5800.0495341.2%30% EtOH No Flavor0.6340.6450.8330.6780.6980.0922481.8%30% EtOH No Flavor 3%0.7210.7630.9120.730.7820.08885430% EtOH No Flavor 5%1.0230.9281.1080.8910.9880.097695FormulationsFormulation components and concentrations affect various aspects of aerosol delivery and sensory experience including, but not limited to, droplet size formed upon aerosolization of a liquid, taste, irritation (independent from droplet size), mouth feel, throat feel, etc. Additionally, formulation can affect the speed and degree of uptake of a drug, such as nicotine, into the bloodstream.In some embodiments, the compositions can be used to produce aerosolized droplets having defined droplet sizes (MMAD). In some embodiments, aerosolization of the compositions using a push mode droplet delivery device provides droplets having an MMAD less than 6 μm, less than 5 μm, less than 4 μm, less than 3 μm, less than 2.5 μm, less than 2 μm, less than 1.5 μm, less than 1.25 μm, less than 1.15 μm, less than 1.05 μm, less 0.95 μm, less than 0.85 μm, less than 0.75 μm, less than 0.65 μm, less than 0.55 μm, or less than 0.5 μm. In some embodiments, aerosolization of the compositions using a push mode droplet delivery device provides droplets having an MMAD from 0.5-3 μm, from 0.5-2.5 μm, from 0.5-2 μm, from 0.5-1.5 μm, from 0.5-1 μm, from 1-1.5 μm, from 1-2 μm, from 1-2.5 μm, or from 2-3 μm. In some embodiments, the droplets have an MMAD from 0.5-1 μm.In some embodiments, compositions herein are composed of water at a concentration of about 80% (w / w) to about 95% (w / w). In some embodiments, the compositions herein comprise about 60% (w / w) to about 80% (w / w) water. In some embodiments, the compositions herein comprise about 80% (w / w) to about 100% (w / w) water. In some embodiments, the compositions herein comprise about 0% (w / w) to about 60% (w / w) water.In some embodiments the composition can have a viscosity from 0.9-2.5 mm2 / s, from 0.9-2 mm2 / s, from 0.9-1.5 mm2 / s, from 1.5-2 mm2 / s, from 1.5-2.5 mm2 / s, or from 2-2.5 mm2 / s, measured at 23 °C.In some embodiments the composition can have a surface tension from 40-70 mN / m, from 40-60 mN / m, from 40-50 mN / m, from 50-70 mN / m, from 50-60 mN / m, from 60-70 mN / m, from 70-80 mN / m, from 80-90 mN / m, or from 90-100 mN / m.

[0052] In some embodiments, compositions herein comprise nicotine at a concentration of 0% (w / w) to 5% (w / w). In some embodiments, the composition comprises nicotine at a concentration from 0.1-2.5% (w / w), 0.1-2% (w / w), 0.1-1.5% (w / w), 0.1-1% (w / w), 0.1-0.5% (w / w), 0.2-1.5% (w / w), 0.2-0.8% (w / w), 0.4-1.0% (w / w), 0.6-1.2% (w / w), or 0.8-1.5% (w / w). In some embodiments, compositions herein comprise nicotine in a concentration of greater than 5% (w / w). In some embodiments, the composition does not include any nicotine in the formulation. Such compositions may be used as a part of a smoking cessation program at the end of downward titration sequence.

[0053] In some embodiments, compositions herein comprise L-lactic acid at a concentration of 0% (w / w) to about 5% (w / w). In some embodiments the composition comprises D-lactic acid or DL-lactic acid. In some embodiments, compositions herein comprise L-lactic acid at a concentration of about 5% (w / w) to about 20% (w / w). In some embodiments, the composition does not include any L-lactic acid. In some embodiments, the composition includes L-lactic acid in a substantially equimolar amount to the nicotine. In some embodiments, the composition includes lactic acid, e.g., L-lactic acid in a molar excess relative to nicotine, for example 100-200 mol %, 100-150%, 100-125 mol %, 125-150 mol %, or 150-200 mol %, relative to the nicotine. Unless specified to the contrary, reference to lactic acid means L-lactic acid.

[0054] In some embodiments, compositions herein comprise of propylene glycol at a concentration of 0% (w / w) to about 20% (w / w). For example, the composition comprises propylene glycol at a concentration of 1-20% (w / w), 1-10% (w / w), 1-5% (w / w), 5-10% (w / w), 5-15% (w / w), or 10-20% (w / w). In some embodiments, compositions herein comprise propylene glycol at a concentration of about 20% (w / w) to about 100% (w / w). In some embodiments, the composition does not include any propylene glycol in the formulation.

[0055] In some embodiments, compositions herein comprise ethanol at a concentration of 0% (w / w) to about 10% (w / w). For example, in embodiments, the composition comprises ethanol at a concentration of 1-10% (w / w), 1-5% (w / w), 2.5-7.5% (w / w), or 5-10% (w / w). In some embodiments, compositions herein comprise ethanol at a concentration of 10% (w / w) to about 100% (w / w). In some embodiments, the composition does not include any ethanol in the formulation.

[0056] In some embodiments, compositions herein comprise L-menthol. The concentration of L-menthol in embodiments can range from about 0.1% (w / w) to about 1.0% (w / w). For example, in embodiments, the composition comprises L-menthol at a concentration from 0.1-1.0% (w / w), 0.1-0.25% (w / w), 0.25-0.5% (w / w), 0.25-0.75% (w / w), or 0.5-1% (w / w). In embodiments, the concentration of L-menthol can be higher than 1.0%. In some embodiments the composition comprises L-menthol in water, ethanol and propylene glycol. For a water and / or water-nicotine based solution, propylene glycol can be between 5% (w / w) to about 15% (w / w) and ethanol can be between 1% (w / w) and about 10% (w / w). For an L-menthol solution at a concentration of 0.8% (w / w) or lower, the minimum amount of ethanol can be 2.5% (w / w), and the minimum amount of propylene glycol can be 10% (w / w). For L-menthol solutions at a concentration of above 0.8% (w / w), ethanol can be between 2.5% (w / w) to 10% (w / w). In some embodiments, the composition having L-menthol at a concentration above 0.8% (w / w) can also include 10% (w / w) propylene glycol.

[0057] In some embodiments, compositions herein comprise WS-23 (2-isopropyl-N,2,3-trimethylbutyramide) in the concentration of 0.1% (w / w) to about 0.5% (w / w). In embodiments, formulations may include WS-23 in a concentration higher than 0.5% (w / w). In some embodiments the composition includes WS-23, water, and ethanol at a concentration of 2.5% (w / w) to about 10% (w / w). In some embodiments, propylene glycol at a concentration of 10% (w / w) can also be included.

[0058] In some embodiments, compositions herein comprise concentrated fruit extracts in the concentration of 0.1% (w / w) to about 5% (w / w). In some embodiments, compositions herein comprise concentrated fruit extracts in the concentration of about 5% (w / w) to about 10% (w / w). In some embodiments, compositions herein comprise of concentrated fruit extracts in concentrations greater than 10% (w / w).

[0059] In embodiments, compositions herein comprising of concentrated fruit extract comprise additional excipients in order to get the fruit extract into water-based solutions. In some embodiments ethanol in the concentration of 1% (w / w) to 10% (w / w) can be included. In some embodiments propylene glycol in the concentration of 1% (w / w) to about 15% (w / w) can be included.

[0060] In embodiments, compositions herein comprising of concentrated fruit extract comprise additional excipients to get the fruit extract into water-based solutions. Ethanol in the concentration of 1% (w / w) to 10% (w / w), in addition to propylene glycol in the concentration of 1% (w / w) to about 15% (w / w), can be included. In some embodiments, ethanol in the concentration of 1% (w / w) to 10% (w / w) may be used without propylene glycol to get the fruit extract into water-based solutions. In some embodiments, propylene glycol in the concentration of 1% (w / w) to about 15% (w / w) may be used without ethanol to get the fruit extract into water-based solutions.

[0061] In some embodiments, compositions herein comprise a cyclodextrin at a concentration of 0.1% (w / w) to about 5% (w / w). Cyclodextrin is used as a solubilizing agent.

[0062] In embodiments, cyclodextrin can be used by itself, or it can be used with ethanol at a concentration of 1% (w / w) to about 10% (w / w). In embodiments, cyclodextrin can be used with ethanol at a concentration greater than 10% (w / w).

[0063] In embodiments, cyclodextrin is used with propylene glycol in a concentration of 1% (w / w) to about 15% (w / w). In embodiments, cyclodextrin is used with propylene glycol at a concentration greater than 15% (w / w).

[0064] In embodiments, cyclodextrin is used with both ethanol and propylene glycol.

[0065] In some embodiments, the compositions comprise an organic acid, for example acetic acid, ascorbic acid, citric acid, fumaric acid, gluconic acid, glycolic acid, maleic acid, malic acid, oleic acid, stearic acid, succinic acid, tartaric acid, ethylenediaminetetraacetic acid (EDTA), salts thereof, or combination thereof. The organic acid (or combination of acids) can be provided at a concentration from 0.05-2.5 wt. %, from 0.05-2.0 wt. %, from 0.05-1.5 wt. %, from 0.05-1 wt. %, from 0.05-0.5 wt., from 0.1-2.5 wt. %, from 0.1-1 wt. %, from 0.5-1.5 wt. %, from 1-2 wt. %, or from 1-2.5 wt. %. In some embodiments, the organic acid can be ascorbic acid, citric acid, lactic acid, EDTA, or a combination thereof. In some embodiments, the organic acid is citric acid, ascorbic acid, EDTA, or a combination thereof. In some embodiments the organic acid is a mixture of citric acid and ascorbic acid, optionally in further combination with EDTA. In some embodiments the organic acid is lactic acid, optionally in further combination with EDTA. In some embodiments the organic acid is lactic acid, optionally in further combination with ascorbic acid, citric acid, and / or EDTA. In some embodiments the organic acid is lactic acid, ascorbic acid, and citric acid, optionally in further combination with EDTA.

[0066] In some embodiments, the composition comprises a carbohydrate. As used herein “carbohydrate” includes carbohydrate derivatives like sugar alcohols. In some embodiments, the composition comprises lactose, mannitol, or a combination thereof.

[0067] In some embodiments, the composition comprises a preservative. In some embodiments, the composition comprises benzalkonium chloride, parabens (e.g., methyl and / or propyl paraben) thymol, benzyl alcohol, sodium bisulfite, sodium metabisulfite, or a combination thereof.

[0068] In some embodiments, the composition comprises a surfactant. In some embodiments, the composition comprises soy lecithin, 1,2-distearoyl-sn-glycero-3-hosphatidylcholine, polysorbates tween 20 or tween 80.

[0069] In some embodiments the composition comprises a polymer, for example polyethylene glycol such a PEG400, a PEG / PPG copolymer such as poloxamer 188, or polyvinyl alcohol.

[0070] In some embodiments, the composition comprises a tonicity agent. In some embodiments the composition comprises sodium chloride, sodium sulfate, or a combination thereof.

[0071] In some embodiments, compositions herein comprise of one or more flavoring chemicals in the concentration of 0.001% (w / w) to about 5% (w / w). In some embodiments, compositions comprise flavoring chemicals at concentrations of greater than 5% (w / w). The flavoring chemicals may be naturally derived or artificial. In some embodiments, the flavoring chemicals may be commercially available in the form of a premixed flavor concentrate. Some non-limiting examples of commercially available flavors that could be used include those manufactured by FLAVORIQ.

[0072] In some embodiments, compositions herein include one or more tobacco flavor(s). The tobacco flavor(s) can comprise of one or more chemicals that may be naturally derived or artificial. In some embodiments, the tobacco flavor(s) may be used in conjunction with one or more non-tobacco characterizing flavor(s) (e.g., vanilla, menthol, mint, chocolate, herb, spice, etc.) that may be naturally derived or artificial. In some embodiments, the tobacco flavor(s) may be commercially available in the form of a premixed flavor concentrate. Some non-limiting examples of commercially available tobacco flavors that could be used include those manufactured by FLAVORIQ including, but not limited to, American Blend Gold (Item No. FQ C003), American Blend Red (Item No. FQ C004), American Blend Silver (Item No. FQ C005), Burley Tobacco (Item No. FQ C006), Cigar Cuba (Item No. FQ C007), Cigar Dom Rep (Item No. FQ C008), Dark Tobacco (Item No. FQ C010), Modified Virginia (Item No. FQ C012), Orient Tobacco Black (Item No. FQ C013), Pipe Tobacco (Item No. FQ C015), Tobacco-Chocolate (Item No. FQ C016), Tobacco-Vanilla (Item No. FQ C020), Virginia Tobacco (Item No. FQ C021).

[0073] In embodiments, flavoring chemicals are used by themselves, or are used with ethanol at a concentration of 1% (w / w) to about 10% (w / w). In embodiments, flavoring chemicals are used with ethanol at a concentration greater than 10% (w / w).

[0074] In embodiments, flavoring chemicals are used with propylene glycol in a concentration of 1% (w / w) to about 15% (w / w). In embodiments, flavoring chemicals are used with propylene glycol at a concentration greater than 15% (w / w).

[0075] In embodiments, flavoring chemicals are used with cyclodextrin in a concentration of 1% (w / w) to about 5% (w / w).

[0076] In embodiments, flavoring chemicals are used with both ethanol and propylene glycol and / or cyclodextrin.

[0077] In preferred embodiments, formulations comprise nicotine at a concentration between 0.1% to 1.8% (w / w) and water at a concentration between 75% to 99% (w / w).

[0078] In some embodiments, hydrochloric acid is used to pH adjust nicotine-containing solutions to a pH range of 9.5 to 7.0. In some embodiments, hydrochloric acid is used to adjust the pH of nicotine-containing solutions to a pH below 7.0.

[0079] In some embodiments, nicotine-containing solutions comprise citric acid monohydrate at a concentration between 0% to 0.13% (w / w). For example, the composition comprises citric acid monohydrate at a concentration from 0.01-0.13% (w / w), 0.01-0.05% (w / w), 0.25-0.5% (w / w), 0.25-0.75% (w / w), 0.5-0.13% (w / w), or 0.75-0.13% (w / w). In some embodiments, nicotine-containing solutions comprise citric acid monohydrate at a concentration higher than 0.13% (w / w).

[0080] In some embodiments, nicotine-containing solutions comprise ascorbic acid at a concentration between 0% to 0.11% (w / w). For example, the composition comprises ascorbic acid at a concentration from 0.01-0.13% (w / w), 0.01-0.05% (w / w), 0.25-0.5% (w / w), 0.25-0.75% (w / w), 0.5-0.13% (w / w), or 0.75-0.13% (w / w). In some embodiments, nicotine-containing solutions comprise ascorbic acid at a concentration higher than 0.11% (w / w).

[0081] In some embodiments, nicotine-containing solutions comprise citric acid monohydrate at a concentration between 0% to 0.13% (w / w) and / or ascorbic acid at a concentration between 0% to 0.11% (w / w).

[0082] In some embodiments, nicotine-containing solutions comprise both citric acid and ascorbic acid.

[0083] In some embodiments, citric acid and / or ascorbic acid are added to a nicotine containing solution to provide a specified pH level.

[0084] In some embodiments, the composition includes nicotine, lactic acid, citric acid, and ascorbic acid, optionally in combination with one or more flavoring chemicals and / or fruit extract, and optionally in combination with propylene glycol and / or ethanol.

[0085] In some embodiments, formulations comprise saccharin at a concentration between 0% to 0.05% (w / w). In some embodiments, formulations comprise saccharin at a concentration higher than 0.05%.

[0086] In some embodiments, the final pH of the formulation is in the range of 4 to 7.

[0087] In some embodiments, the final pH of the formulation is in the range of 7 to 9.5.

[0088] In some embodiments, the composition has a pH from 4-8, 4-6, 4.4-5.8, 4.6-5.4, 4.8-5.2, 5.0-5.4, 5.2-5.6, or 5.4-5.8. In some embodiments, the composition has a pH from 4-4.5, 4.25-4.75, 4.5-5, 4.75-5.25, 5-5.5, 5.25-5.75, 5.5-6, 5.75-6.25, 6-6.5, 6.25-6.75, 6.5-7, 6.75-7.25, 7-7.5, 7.25-7.75, or 7.5-8.

[0089] Also disclosed herein are methods of making the disclosed compositions and compositions made by the disclosed methods. In some embodiments a solution of nicotine hydrochloride is prepared. In some embodiments a solution of nicotine lactate is prepared. In embodiments, the pH of the prepared solution is from 7-10, from 7-9, from 7-8, from 7-7.5, from 7.5-8, or from 7.5-8.5. In embodiments, to the solution is then added a sufficient quantity of organic acid to provide a solution having a pH from 4-6, 4.4-5.8, 4.6-5.4, 4.8-5.2, 5.0-5.4, 5.2-5.6, 5.4-5.8, 5-7, 5-7.5, 5-6, 5.5-6.5, or 6-7. In embodiments, the pH is from 4.4-5.8 or 4.8-5.2. In embodiments, the organic acid is citric acid, ascorbic acid, EDTA, or a combination thereof. In certain embodiments the organic acid is citric acid and ascorbic acid, optionally in further combination with EDTA. In some embodiments, the organic acid is lactic acid, optionally in combination with one or more of citric acid, ascorbic acid and EDTA. In some embodiments, the organic acid is lactic acid, optionally in combination with EDTA. In some embodiments, the organic acid lactic acid, citric acid, and ascorbic acid, optionally in further combination with EDTA.

[0090] In embodiments, the formulation comprises about 1.2% (w / w) nicotine with enough hydrochloric acid to adjust the pH to 7.0-7.8. Then, citric acid monohydrate is added in a concentration of about 0.13% (w / w) and saccharin is added in a concentration of about 0.05% (w / w). The remainder of the formulation is pure water. The final pH of the formulation is between 4.4-5.8.

[0091] In embodiments, the formulation comprises about 1.2% (w / w) nicotine with enough hydrochloric acid to adjust the pH to 7.0-7.8. Then, ascorbic acid is added in a concentration of about 0.11% (w / w) and saccharin is added in a concentration of about 0.05% (w / w). The remainder of the formulation is pure water. The final pH of the formulation is between 4.4-5.8.

[0092] In embodiments, the formulation comprises about 1.2% (w / w) nicotine with enough hydrochloric acid to adjust the pH to 7.4-8.2. Then, citric acid monohydrate is added in a concentration of about 0.13% (w / w), ascorbic acid is added in a concentration of about 0.11% (w / w), and saccharin is added in a concentration of about 0.05% (w / w). The remainder of the formulation is pure water. The final pH of the formulation is between 4.4-5.8.

[0093] In embodiments, the formulation comprises only excipients approved by the U.S. Food and Drug Administration (FDA) for inhalation as follows:

[0094] Nicotine 0.6% to 1.2% (w / w)

[0095] Hydrochloric acid as a pH adjuster

[0096] Citric acid monohydrate 0% to 0.13% (w / w)

[0097] Ascorbic acid 0% to 0.11% (w / w)

[0098] Saccharin 0% to 0.05% (w / w)

[0099] DI Type 1 waterEXEMPLARY APPLICATIONS

[0100] In some embodiments, the formulations of the present application are provided in cartridges for use with a droplet delivery device. An exemplary push mode type droplet delivery device is depicted in FIG. 5. The push mode droplet delivery device represented in this embodiment has three components—a handpiece (1600), an ejector bracket (400), and a cartridge (1100). The handpiece contains a vibrating member (800), which consists of a piezoelectric transducer (801) bonded to a horn (802). The ejector bracket (400) is connected to the handpiece (1600) via magnets. The ejector bracket (400) has an ejector plate (300) held by an ejector plate carrier, preferably positioned at a 3 degree angle relative to the face of the vibrating member tip. The ejector bracket (400) holds a membrane (401), which touches the backside of the ejector plate (300) and separates the ejector plate (300) from the vibrating member (800). The tip of the vibrating member (800) contacts the membrane (401) and puts a force onto the ejector plate (300). When the piezoelectric transducer (801) vibrates, it transfers the energy to the horn (802) and to the ejector plate (300). The vibrating member (800) tip transfers the energy through the membrane (401) to the ejector plate (300). The ejector plate (300) vibrates. The vibrating member (800) tip also creates some pressure and pushes liquid into the ejector plate (300). The vibrating member (800) may also be creating a pumping action to pump liquid to the ejector plate (300).

[0101] The cartridge (1100) holds the fluid to be aerosolized and is operably coupled to the ejector bracket (400), providing fluid supply to the ejector plate (300). The user inhales through a mouthpiece (700) on the cartridge (1100).

[0102] In some embodiments, the cartridge comprises from 0.5-3 mL, from 0.5-2.5 mL, from 0.5-2.0 mL, from 0.5-1.5 mL, from 0.5-1 mL, from 1-1.5 mL, from 1-2.0 mL, from 1-2.5 mL, from 1.5-2.0 mL, from 1.5-2.5 mL, from 1.5-3.0 mL, from 2-2.5 mL, from 2-3 mL, or from 2.5-3.0 mL. In some embodiments, the cartridges can be composed of cyclohexylenedimethylene terephthalate glycol-modified plastic.

[0103] In some embodiments, formulations of the present application are used with droplet delivery devices as smoking cessation products.

[0104] In some embodiments, formulations of the present application are used with droplet delivery devices as nicotine replacement therapies (NRTs).

[0105] In some embodiments, formulations of the present application are used with droplet delivery devices for smoking cessation or reduction. In some embodiments, the formulations are provided in kits containing a plurality of cartridges including the disclosed compositions. The compositions may be included at a variety of nicotine concentrations, for example 1.5 wt. %, 1.25 wt. %, 1.0 wt. %, 0.75 wt. %, 0.5 wt. %, 0.25 wt. %, and 0 wt. %. A user first consumes the highest concentration nicotine compositions and then steps down to the next lower concentration. By gradually decreasing the amount of inhaled nicotine, a user experiences reduced or no withdrawal symptoms often experienced with acute cessation. In some embodiments a plurality of cartridges are provided, in which a first portion of cartridges are provided having a nicotine concentration as disclosed herein, e.g., from 0.1-2.5% (w / w), 0.1-2% (w / w), 0.1-1.5% (w / w), 0.1-1% (w / w), 0.1-0.5% (w / w), 0.2-1.5% (w / w), 0.2-0.8% (w / w), 0.4-1.0% (w / w), 0.6-1.2% (w / w), or 0.8-1.5% (w / w). A second portion is also provided having a reduced concentration of nicotine, e.g., 50-75%, 75-95%, 80-95%, or 90-95% relative to the first portion. Additional portions may be provided, each having a similarly reduced concentration relative to the previous portion. After the user has consumed the first portion, he or she then consumes the second portion thereby reducing nicotine intake. Continuing through a series of portions, each portion having reduced nicotine relative to the previous, allows the user to reduce nicotine consumption with reduced or no withdrawal symptoms.

[0106] In some embodiments, formulations of the present application are used to provide therapeutic levels of nicotine for the treatment of Long Covid, including brain fog, fatigue, and sensory changes (i.e., loss of the sense of smell or taste).

[0107] In some embodiments, formulations of the present application are used with droplet delivery devices as consumer products.

[0108] In some embodiments, a formulation of the present application is prescribed by a physician or doctor for use with a droplet delivery device. In some embodiments, a formulation of the present application is available over-the-counter for use with a droplet delivery device. In embodiments, a formulation of the present application is available as a consumer product for use with a droplet delivery device.

[0109] In some embodiments, a formulation of the present application is prescribed with a droplet delivery device as part of a smoking cessation program.

[0110] In some embodiments, a formulation of the present application is prescribed with a droplet delivery device as part of a nicotine cessation or nicotine tapering program.

[0111] In some embodiments, a formulation of the present application is prescribed with a droplet delivery device as an NRT.

[0112] In preferred embodiments, the formulations of the present application are used with non-heated droplet delivery devices.

[0113] In preferred embodiments, the formulations of the present application are used with a push mode type of droplet delivery device, including devices described in U.S. Pat. No. 11,793,945 entitled “Droplet Delivery Device with Push Ejection,” PCT / US25 / 49918 entitled “Optimization of Droplet Delivery Device with Ejector Plate,” and U.S. Provisional Pat. App. No. 63 / 891,593 entitled “Multi-Cartridge Push Mode Droplet Delivery Device,” which are all incorporated herein by reference in their entireties.

[0114] In embodiments, the formulations of the present application are used with a ring mode type of droplet delivery device.

[0115] In embodiments, the formulations of the present application are used with a droplet delivery device comprising a heating element.

[0116] In embodiments, the formulations of the present application are used with any device delivering a nicotine solution.

[0117] Various embodiments of the invention have been described. It will, however, be evident that various modifications and changes may be made thereto, and additional embodiments may be implemented, without departing from the broader scope of the invention as set forth in this disclosure. This specification is to be regarded in an illustrative rather than a restrictive sense.

Claims

1. An aqueous nicotine composition for use with a droplet delivery device, the composition comprising nicotine or a salt thereof, water in an amount of at least 50 wt. %, and one or more organic acids comprising lactic acid or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, or a combination thereof.

2. The composition of claim 1, wherein the one or more organic acids comprise lactic acid or a salt thereof.

3. The composition of claim 1, wherein the one or more organic acids comprise ascorbic acid or a salt thereof and citric acid or a salt thereof.

4. The composition of claim 3, wherein the composition comprises nicotine ascorbate and nicotine citrate.

5. The composition of claim 1, wherein the composition comprises nicotine at a concentration from 0.1 wt. % to 2.5 wt. %.

6. The composition of claim 5, wherein the composition comprises nicotine at a concentration from 0.6 wt. % to 1.2 wt. %.

7. The composition of claim 1, wherein the composition comprises water in an amount of at least 80 wt. %.

8. The composition of claim 1, wherein the composition has a pH from 4.4 to 5.8.

9. The composition of claim 8, wherein the composition has a pH from 5.0 to 5.4.

10. The composition of claim 1, wherein aerosolization of the composition using a push-mode droplet delivery device produces droplets having an average MMAD from 0.5 micrometers to 3 micrometers.

11. The composition of claim 1, wherein the composition has a viscosity from 0.9 mm2 / s to 2.5 mm2 / s measured at 23 degrees Celsius.

12. The composition of claim 1, wherein the composition has a surface tension from 40 mN / m to 70 mN / m.

13. The composition of claim 1, wherein the composition comprises propylene glycol in an amount from 1 wt. % to 20 wt. %.

14. The composition of claim 1, wherein the composition comprises ethanol in an amount from 1 wt. % to 10 wt. %.

15. The composition of claim 1, wherein the composition comprises menthol in an amount from 0.1 wt. % to 1.0 wt. %.

16. The composition of claim 1, wherein the composition comprises a flavorant.

17. The composition of claim 16, wherein the flavorant comprises a fruit extract.

18. The composition of claim 16, wherein the flavorant comprises a tobacco flavor.

19. The composition of claim 1, wherein the composition comprises a sweetener.

20. The composition of claim 1, wherein the composition comprises a surfactant.

21. The composition of claim 1, wherein the composition comprises a polymer.

22. The composition of claim 1, wherein the composition comprises a cyclodextrin.

23. A droplet delivery device replaceable cartridge comprising a container and an aqueous nicotine composition disposed in the container, wherein the aqueous nicotine composition comprises nicotine or a salt thereof, water in an amount of at least 50 wt. %, and one or more organic acids comprising lactic acid or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, or a combination thereof, and wherein aerosolization of the aqueous nicotine composition using a push-mode droplet delivery device produces droplets having an average MMAD less than 3 micrometers.

24. The cartridge of claim 23, wherein the container comprises cyclohexylenedimethylene terephthalate glycol-modified plastic.

25. The cartridge of claim 23, wherein the container contains from 0.5 mL to 3 mL of the aqueous nicotine composition.

26. A droplet delivery device comprising the cartridge of claim 23 and an electronically actuated ejector in fluid communication with the aqueous nicotine composition.

27. The droplet delivery device of claim 26, wherein the electronically actuated ejector is configured for push-mode ejection.

28. A smoking cessation system comprising a kit comprising a plurality of cartridges, wherein a first cartridge includes a first aqueous nicotine composition comprising nicotine or a salt thereof at a first concentration, a second cartridge includes a second aqueous nicotine composition comprising nicotine or a salt thereof at a second concentration, the second concentration is lower than the first concentration, and each of the first and second aqueous nicotine compositions comprises water and one or more organic acids selected from lactic acid, ascorbic acid, citric acid, salts thereof, and combinations thereof.

29. The smoking cessation system of claim 28, wherein the second concentration is from 50% to 75% of the first concentration.

30. The smoking cessation system of claim 28, wherein the plurality of cartridges further comprises a third cartridge including a third aqueous nicotine composition comprising nicotine or a salt thereof at a third concentration lower than the second concentration.